|
1）Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-92
|
|
|
|
2）Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039-43
|
|
|
|
|
|
3）Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations. Cancer Res. 2008; 68: 9479-87
|
|
|
|
|
|
4）Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3: 75ra26
|
|
|
|
|
|
5）Ng KP, Hillmer AM, Chuah CT, et al. Common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012; 18: 512-28
|
|
|
|
|
|
6）Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLos Med. 2007; 4: 1669-79
|
|
|
|
|
|
7）Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther. 2009; 8: 3173-80
|
|
|
|
|
|
8）Faber AC, Corcoran RB, Ebi H, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011; 1: 352-65
|
|
|
|
|
|
9）Juan WC, Roca X, Ong ST. Identification of cis-acting elements and splicing factors involved in the regulation of BIM Pre-mRNA splicing. PLoS One. 2014; 9: e95210
|
|
|
|
|
|
10）Ebi H, Oze I, Nakagawa T, et al. Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. J Thorac Oncol. in press
|
|
|
|
|
|
11）Lee JH, Lin YL, Hsu WH, et al. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol. 2014; 9: 1385-92
|
|
|
|
|
|
12）Lee JK, Shin JY, Kim S, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol. 2013; 24: 2080-7
|
|
|
|
|
|
13）Isobe K, Hata Y, Tochigi N, et al. Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation. J Thorac Oncol. 2014; 9: 483-7
|
|
|
|
|
|
14）Zhao M, Zhang Y, Cai W, et al. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 2014; 120: 2299-307
|
|
|
|
|
|
15）Shao YY, Chang YL, Huang CY, et al. The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma. Oncology. 2013; 85: 312-6
|
|
|
|
|
|
16）Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-84
|
|
|
|
|
|
17）医薬品インタビューフォーム「抗悪性腫瘍剤 ヒストン脱アセチル化酵素阻害剤 ゾリンザⓇ カプセル100mg」2012年3月改訂（第3版）
|
|
|
|
|
|
18）Xargay-Torrent S, López-Guerra M, Saborit-Villarryoma I, et al. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. 2011; 17: 3956-68
|
|
|
|
|
|
19）Nakagawa T, Takeuchi S, Yamada T, et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 2013; 73: 2428-34
|
|
|
|
|